association

Full identifier: http://purl.org/np/RAJbwkpbyScggoskTQAcOZy_ir_X-V2i55sh7TC9Zbz3I#association

Assigned to 1 class:

Minted in Nanopublication

 RAJbwkpbyS comment approve/disapprove edit as derived nanopublication create new with same template

This is a local identifier minted within the nanopublication. http://purl.org/np/RAJbwkpbyS...#association This association http://www.w3.org/2000/01/rdf-schema#label has label (this is a literal) "risperidone is an atypical antipsychotic agent indicated for treatment of schizophrenia in adults 1 1 alone or in combination with lithium or valproate for the short term treatment of acute manic or mixed episodes associated with bipolar i disorder in adults 1 2 due to janssen pharmaceuticals corporation s marketing exclusivity rights this drug product is not labeled for use in pediatric patients with schizophrenia bipolar mania or autistic disorder 1 1 1 2 1 3 adults risperidone is indicated for the acute and maintenance treatment of schizophrenia see clinical studies 14 1 adolescents due to janssen pharmaceuticals corporation s marketing exclusivity rights this drug product is not labeled for use in pediatric patients with schizophrenia pediatric use information for the treatment of pediatric patients with schizophrenia 13 to 17 years of age is approved for janssen pharmaceuticals corporation s risperidone drug products monotherapy adults and pediatrics risperidone is indicated for the short term treatment of acute manic or mixed episodes associated with bipolar i disorder in adults see clinical studies 14 2 due to janssen pharmaceuticals corporation s marketing exclusivity rights this drug product is not labeled for use in pediatric patients with bipolar mania pediatric use information for the treatment of pediatric patients with bipolar mania 1 to 17 years of age is approved for janssen pharmaceuticals corporation s risperidone drug products combination therapy adults the combination of risperidone with lithium or valproate is indicated for the short term treatment of acute manic or mixed episodes associated with bipolar i disorder see clinical studies 14 3 pediatrics due to janssen pharmaceuticals corporation s marketing exclusivity rights this drug product is not labeled for use in pediatric patients with irritability associated with autistic disorder information regarding the treatment of pediatric patients with irritability associated with autistic disorder 5 to 16 years of age is approved for janssen pharmaceuticals corporation s risperidone drug products" .
This is the identifier for this whole nanopublication. http://purl.org/np/RAJbwkpbyS... This nanopublication date and time when the nanopublication was created http://purl.org/dc/terms/created was created on (this is a literal) "2021-06-14T08:57:43.009+02:00" .
This is the identifier for this whole nanopublication. http://purl.org/np/RAJbwkpbyS... This nanopublication links to the assertion template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate was created from the assertion template http://purl.org/np/RAManV5GZI... RAManV5GZI .
This is the identifier for this whole nanopublication. http://purl.org/np/RAJbwkpbyS... This nanopublication links to the provenance template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate was created from the provenance template http://purl.org/np/RANwQa4ICW... RANwQa4ICW .
This is the identifier for this whole nanopublication. http://purl.org/np/RAJbwkpbyS... This nanopublication links to the publication info template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate was created from the publication info template http://purl.org/np/RAA2MfqdBC... RAA2MfqdBC .
This is a local identifier minted within the nanopublication. http://purl.org/np/RAJbwkpbyS...#sig sig http://purl.org/nanopub/x/hasSignatureTarget has as target This is the identifier for this whole nanopublication. http://purl.org/np/RAJbwkpbyS... this nanopublication .
This is a local identifier minted within the nanopublication. http://purl.org/np/RAJbwkpbyS...#sig sig http://purl.org/nanopub/x/hasAlgorithm has the algorithm (this is a literal) "RSA" .

Leoni Bücken, 14 Jun 2021, 06:57:43 UTC

References

Nanopublication Part Subject Predicate Object Published By Published On
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-14T06:57:43.009Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
risperidone is an atypical antipsychotic agent indicated for treatment of schizophrenia in adults 1 1 alone or in combination with lithium or valproate for the short term treatment of acute manic or mixed episodes associated with bipolar i disorder in adults 1 2 due to janssen pharmaceuticals corporation s marketing exclusivity rights this drug product is not labeled for use in pediatric patients with schizophrenia bipolar mania or autistic disorder 1 1 1 2 1 3 adults risperidone is indicated for the acute and maintenance treatment of schizophrenia see clinical studies 14 1 adolescents due to janssen pharmaceuticals corporation s marketing exclusivity rights this drug product is not labeled for use in pediatric patients with schizophrenia pediatric use information for the treatment of pediatric patients with schizophrenia 13 to 17 years of age is approved for janssen pharmaceuticals corporation s risperidone drug products monotherapy adults and pediatrics risperidone is indicated for the short term treatment of acute manic or mixed episodes associated with bipolar i disorder in adults see clinical studies 14 2 due to janssen pharmaceuticals corporation s marketing exclusivity rights this drug product is not labeled for use in pediatric patients with bipolar mania pediatric use information for the treatment of pediatric patients with bipolar mania 1 to 17 years of age is approved for janssen pharmaceuticals corporation s risperidone drug products combination therapy adults the combination of risperidone with lithium or valproate is indicated for the short term treatment of acute manic or mixed episodes associated with bipolar i disorder see clinical studies 14 3 pediatrics due to janssen pharmaceuticals corporation s marketing exclusivity rights this drug product is not labeled for use in pediatric patients with irritability associated with autistic disorder information regarding the treatment of pediatric patients with irritability associated with autistic disorder 5 to 16 years of age is approved for janssen pharmaceuticals corporation s risperidone drug products
Leoni Bücken
2021-06-14T06:57:43.009Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-14T06:57:43.009Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-14T06:57:43.009Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-14T06:57:43.009Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-14T06:57:43.009Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-14T06:57:43.009Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-14T06:57:43.009Z

Raw

TriG(txt), JSON-LD(txt), N-Quads(txt), XML(txt)